In addition, SHP2 mutations and the SHP2 binding protein, Gab2, are associated with hyperactivation of the ERK, AKT and STAT5 pathways in JMML, suggesting novel approaches to JMML therapy (76). The gene discussed is AKT1; the disease is juvenile myelomonocytic leukemia.